ASNR Study Groups

ASNR members may join any of our Study Groups when joining or renewing membership. Contact for more information.

Co-Chairs: Tammie Benzinger, MD, PhD; Clifford Jack, MD
Vice Chair: Petrice Cogswell, MD, PhD
This group was created to facilitate the exchange of information in the field of Alzheimer’s Disease and Dementia, with a specific interest in sharing information about the diagnosis, treatment, and research of amyloid-related imaging abnormalities (ARIA).

Co-Chairs: Bruce Wasserman, MD; David Saloner, MD
The goal of this study group is to advance our understanding of cerebrovascular diseases by developing and support vessel wall imaging protocols and clinical/translational studies. Objectives include:

  • Develop uniform protocols for clinical implementation and reimbursement.
  • Stimulate research in the field, including multicenter investigations of the pathophysiology and risk factors of neurovascular disease.
  • Attract people with similar interests in vessel wall imaging from around the world.
  • Promote education and teaching mechanisms in the field, and present a unified voice for achieving vendor support for protocol development.

Co-Chairs: Vince Kumar, MD; Michael Zeineh, MD-PhD
The goal of this study group is to facilitate the exchange of information and knowledge amongst experts and foster collaborative research in functional and diffusion MRI.

Co-Chairs: Ramon Barajas Jr., MD; Jana Ivanidze, MD, PhD
Formerly the Imaging Genomics and Radiomics Study Group. This study group focuses on the application of PET-guided diagnosis and treatment of primary and metastatic brain tumors, attempting to identify further areas of exploration and multi-society collaboration for the establishment of consensus imaging guidelines, novel translational radiotracer development, and reimbursement advocacy; with a patient centered emphasis.

Objectives include:

  • Connect study group members with current evidence for clinical utility of validated radiotracers and opportunities for improved brain tumor extent delineation, treatment planning and response assessment.
  • Leverage member knowledge and expertise toward translational advancement of novel radiotracers.
  • Provide current evidence and clinical limitations of theranostic approaches with an emphasis on collaborative multi-societal drafting of multi-specialty consensus guidelines regarding applications of PET in Neuro-Oncology.
  • Undertake reimbursement advocacy for clinically useful PET radiotracers and theranostic agents.

Co-Chairs: Greg Zaharchuk, MD; Peter Chang, MD
This study group was created for the purposes of facilitating the exchange of information and knowledge amongst experts and fostering collaborative research that will propel neuroradiology in the next phase of its evolution, ensuring that neuroradiologists will provide the best possible care to their patients.